BHIVA continues to recommend Pre-Exposure Prophylaxis (PrEP)

Tuesday 6 February 2018

Pre-Exposure Prophylaxis (PrEP) is a safe intervention that will reduce the risk of becoming infected with HIV by around 90%, as shown conclusively in the PROUD trial (2016.) The British HIV Association (BHIVA) therefore strongly supports the use of PrEP for those at high risk of HIV infection. This is in line with World Health Organisation recommendations and the view of NICE, which has evaluated PrEP using Truvada, finding it to be highly effective.

PrEP became available in Scotland and Wales in July 2017 but in England is subject to a second implementation trial, IMPACT. This study is open to 10,000 people in sexual health clinics over three years and is being rolled out across the country, with some clinics where it is available already reported to be significantly oversubscribed.

The evidence gathered for the benefits of PrEP for the individual, for clinical services and for the wider public health, is compelling. We recommend that PrEP should be made available to all individuals at high risk of infection within a comprehensive HIV prevention package.


Ends
For further information, please contact Jo Josh: 07787 530 922
jo@commsbiz.com
 


 


About BHIVA

Founded in 1995, BHIVA is the leading professional organisation committed to providing excellence in the care of those living with and affected by HIV. It acts as a national advisory body to professions and other organisations on all aspects of HIV care. BHIVA also provides a national platform for HIV care and contributes representatives for international, national and local committees dealing with HIV care. In addition, BHIVA works to promote undergraduate, postgraduate and continuing medical education within HIV care.     www.bhiva.org    @BritishHIVAssoc